Analysts Set Heartflow, Inc. (NASDAQ:HTFL) Target Price at $37.67

Heartflow, Inc. (NASDAQ:HTFL) has been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $37.00.

Several brokerages recently weighed in on HTFL. JPMorgan Chase & Co. dropped their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Canaccord Genuity Group dropped their target price on Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday. Wells Fargo & Company boosted their target price on Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, William Blair began coverage on Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock.

Heartflow Trading Down 12.2%

Shares of NASDAQ:HTFL opened at $28.32 on Friday. Heartflow has a 12-month low of $20.13 and a 12-month high of $41.22. The business’s fifty day simple moving average is $27.28 and its 200-day simple moving average is $28.87. The company has a market capitalization of $2.44 billion and a PE ratio of -9.11.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. The company’s quarterly revenue was up 41.3% compared to the same quarter last year. Research analysts predict that Heartflow will post -0.78 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total transaction of $27,732,167.11. Following the transaction, the insider directly owned 8,448,158 shares in the company, valued at $246,939,658.34. The trade was a 10.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Julie A. Cullivan sold 9,122 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total value of $228,050.00. Following the transaction, the director owned 27,291 shares in the company, valued at approximately $682,275. This trade represents a 25.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,205,874 shares of company stock valued at $64,166,729 in the last 90 days. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Heartflow

Several large investors have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow during the 4th quarter valued at about $27,000. TFC Financial Management Inc. purchased a new stake in Heartflow during the 3rd quarter valued at about $40,000. Russell Investments Group Ltd. purchased a new stake in Heartflow during the 4th quarter valued at about $45,000. Legal & General Group Plc purchased a new stake in Heartflow during the 3rd quarter valued at about $59,000. Finally, Strs Ohio purchased a new stake in Heartflow during the 4th quarter valued at about $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.